Hologic (NASDAQ:HOLX) Downgraded by Wall Street Zen to "Hold"

Key Points

• Hologic (NASDAQ:HOLX) was downgraded from a "buy" rating to a "hold" rating by Wall Street Zen, signaling a more cautious outlook on the company's stock.
• Despite the downgrade, several analysts have given Hologic an average rating of "Moderate Buy" and set a target price of $79.38 based on recent ratings from various research firms.
• CEO Stephen P. Macmillan sold over 138,000 shares of Hologic stock, representing a 10.08% decrease in his holdings, raising potential concerns for investors regarding insider confidence.

Hologic (NASDAQ:HOLX - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Wednesday.

A number of other equities research analysts have also recently issued reports on HOLX. Stephens reiterated an "overweight" rating and set a $78.00 target price on shares of Hologic in a research report on Thursday, September 18th. Evercore ISI raised their price objective on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Argus raised their price objective on shares of Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a research report on Friday, September 19th. Morgan Stanley raised their price objective on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Finally, UBS Group raised their price objective on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $79.38.

Hologic Trading Up 0.5%

Shares of Hologic stock opened at $67.49 on Wednesday. The stock has a market capitalization of $15.01 billion, a P/E ratio of 28.00, a price-to-earnings-growth ratio of 2.43 and a beta of 0.57. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The company has a 50-day simple moving average of $66.88 and a 200 day simple moving average of $62.97. Hologic has a 12-month low of $51.90 and a 12-month high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the company posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts expect that Hologic will post 4.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares of the company's stock, valued at $82,682,769.28. This trade represents a 10.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.88% of the stock is owned by insiders.

Institutional Trading of Hologic

Several hedge funds have recently bought and sold shares of the stock. Chung Wu Investment Group LLC acquired a new stake in shares of Hologic in the second quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 273 shares during the last quarter. Loomis Sayles & Co. L P acquired a new stake in shares of Hologic in the second quarter valued at approximately $33,000. Zions Bancorporation National Association UT acquired a new stake in shares of Hologic in the first quarter valued at approximately $34,000. Finally, Cromwell Holdings LLC raised its holdings in shares of Hologic by 307.0% in the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock valued at $38,000 after purchasing an additional 436 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.